Table 2.

Characteristics of studies of interferon or pegylated-interferon treatment of chronic HCV-infected hemodialysis patients with long-term HCV RNA outcomes after transplantation

Study, Country, Year	Overall Sample Size (n)	Number with SVR (n)	Number with Long-Term HCV RNA Outcomes (n)	Treatment Dosea	Treatment Duration (mo)b	Long-Term Follow-Up, Median (mo)
Studies with long-term HCV RNA outcomes after interferon
Izopet, France, 1997	23	13	2	3	ND	21
Campistol, Spain, 1999c	19	11	3	3	6	20
Huraib, Saudi Arabia, 1999	17	12	2	3	12	23
Casanovas-Taltavull, Spain, 2001	29	18	9	3	12	50
Huraib, Saudi Arabia, 2001c	11	4	4	3	12	12
Espinosa, Spain, 2001	13	6	1	3	12	27
Kamar, France, 2003	55	21	16	3	6 (n = 3) 12 (n = 13)	24
Buargub, Libya, 2006	35	9	1	3	12	12
Studies with long-term HCV RNA outcomes after pegylated-interferon
Bruchfeld, Sweden, 2006	6	3	2	135 (α-2a), n = 1 50 (α-2b), n = 1 200–300 daily (RBV)	6 (n = 1) 12 (n = 1)	5
Amarapurkar, India, 2007	6	3	3	1.0/kg (α-2b)	6	6
Kose, Turkey, 2009	26	9	2	135 (α-2a)	12	24
All transplant	240	109	45	Variable	6 (n = 10) 12 (n = 33)	20

α-2a, pegylated-interferon alpha-2a; α-2b, pegylated-interferon alpha-2b; ND, not documented; RBV, ribavirin; TIW, three times weekly.

^aDoses presented for interferon are in million units, three times weekly, and for pegylated interferon alpha-2a or 2b are in micrograms, once weekly. When studies used more than one treatment dose, the numbers reported are based on the group with long-term data.

^bIntended treatment duration in months. When studies used different durations, the numbers reported in parentheses are from the group with long-term data. More recent studies selected treatment duration based on HCV genotype with 12 months treatment for genotypes 1 or 4 and 6 months for genotypes 2 or 3.

^cRandomized controlled trial comparing treated patients versus untreated controls. Sample size reported is the treatment group only.